At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 166 enrolled
Drug / intervention
Belataceptdrug
Likely dose
Belatacept 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Belatacept Immunosuppression Therapy in Post-Transplant Kidney Recipients: Comparison of 4-Week and 8-Week Dosing Intervals
In Brief
A Phase 4 clinical trial evaluating Belatacept for Kidney Transplantation. Completed, enrolled 166 participants across 2 sites.
Detailed Summary
The purpose of this study is to transition patients who have been stable on Belatacept for one year after kidney transplant from standard 4-week to an investigational 8-week belatacept dosing schedule. The investigators hypothesize that renal function and acute rejection rates will be non-inferior with 8-week belatacept dosing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionAug 2019
TodayJul 2026
First PostedSep 25, 2015
Enrollment StartSep 1, 2015
Primary CompletionAug 29, 2019
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 10.8 years ago
Interventions
Belataceptdrug
Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.